Bites of Bio

Is ApoB a better predictor of heart disease risk than LDL cholesterol?

Share



Gloved hand holding a blood sample tube in a clinical laboratory
Credit: Unsplash

Apolipoprotein B (ApoB) testing can reveal cholesterol-related cardiovascular risk that a conventional low-density lipoprotein cholesterol (LDL-C) result may underestimate, according to the 2026 American College of Cardiology and American Heart Association dyslipidemia guideline. Two September 2026 papers in the Journal of Clinical Lipidology and JACC: Advances agree that ApoB measures atherogenic particle burden, but disagree over how widely the additional blood test should be used.

LDL cholesterol and ApoB measure different features of the same risk

Low-density lipoprotein (LDL) particles transport cholesterol through the bloodstream. LDL cholesterol (LDL-C), traditionally the main treatment target, measures the mass of cholesterol contained inside these particles, not how many particles are present. An LDL-C result can therefore look similar in two people with different numbers of LDL particles.

Each atherogenic lipoprotein particle, including LDL, very-low-density lipoprotein (VLDL), and lipoprotein(a), contains one ApoB molecule. Measuring ApoB concentration provides an estimate of how many of these particles circulate in the blood. The test is reported as mass concentration, usually in milligrams per deciliter, rather than a literal particle count.

This matters because particles must enter and become retained in the artery wall to contribute to atherosclerotic plaque. The amount of cholesterol each particle carries varies. When particles are relatively cholesterol-depleted, especially in some people with insulin resistance or elevated triglycerides, LDL-C may underrepresent the number of potentially atherogenic particles.

Non-HDL cholesterol captures more than LDL cholesterol without another blood test

Non-high-density lipoprotein cholesterol (non-HDL-C) is calculated by subtracting high-density lipoprotein cholesterol (HDL-C) from total cholesterol. Unlike LDL-C alone, it includes cholesterol carried by LDL, triglyceride-rich remnant particles and lipoprotein(a). It is a measure of cholesterol mass, however, not particle number.

For example, a person with total cholesterol of 190 mg/dL and HDL-C of 50 mg/dL has a non-HDL-C of 140 mg/dL. This example is arithmetic, not a diagnosis or an individualized target. The appropriate LDL-C and non-HDL-C goals depend on the person’s cardiovascular risk.

The 2026 guideline recommends reporting non-HDL-C routinely and prefers modern Martin/Hopkins or Sampson/NIH equations over the older Friedewald equation when estimating LDL-C. Better LDL-C estimation can reduce disagreement between standard cholesterol results and ApoB in some patients.

Disagreement between cholesterol mass and particle number matters most in certain patients

The new guideline recommends that measuring ApoB is reasonable for adults already receiving lipid-lowering therapy, particularly those with established atherosclerotic cardiovascular disease, diabetes, cardiovascular-kidney-metabolic conditions or elevated triglycerides, when LDL-C or non-HDL-C targets have been met. It also says ApoB testing may be reasonable in selected untreated adults to refine risk or characterize inherited lipid disorders.

Such recommendations are selective, rather than universal. A person whose LDL-C is clearly high, or whose overall cardiovascular risk already warrants treatment, may not need ApoB testing before a clinician recommends cholesterol-lowering therapy.

The same risk-factor principle applies to visceral fat and metabolic health and to insulin resistance in muscle. Neither article establishes the value of ApoB testing directly, but both explain why metabolic disease may accompany altered lipid biology.

September research challenges how often conventional targets agree with ApoB

In an original analysis published September 18 in the Journal of Clinical Lipidology, Justine Cole and colleagues examined data from the US National Health and Nutrition Examination Survey. They compared ApoB with LDL-C estimated using the Martin/Hopkins, modified Sampson and Friedewald equations, assessing whether people at LDL-C targets also met corresponding ApoB targets.

The investigators reported meaningful discordance even with modern LDL-C estimates. Their analysis found that some individuals meeting LDL-C thresholds did not meet ApoB thresholds, raising questions about whether restricting ApoB testing to after conventional goals are achieved will identify all relevant residual risk.

This was an analysis of measured biomarkers and their agreement with different targets, not a randomized test of ApoB-guided treatment. Its conclusion depends partly on how corresponding ApoB thresholds are defined. Discordance alone does not establish that ordering ApoB routinely improves clinical outcomes.

Other experts argue that modern LDL estimates make selective ApoB testing sufficient

A September 30 JACC: Advances viewpoint by Alexander Razavi and colleagues agreed that ApoB is a direct indicator of atherogenic particle number but argued against universal testing. The authors noted that modern LDL-C estimation and non-HDL-C targets can narrow discordance and that many treatment decisions are already clear from standard lipids, coronary calcium or overall cardiovascular risk.

They emphasized ApoB testing where the answer is likely to change a treatment decision, such as persistent risk in a patient with diabetes or elevated triglycerides despite apparently satisfactory LDL-C. The viewpoint is expert interpretation, not a new randomized clinical trial, and should not be presented as though it refutes every observed discrepancy in the NHANES analysis.

The disagreement is therefore about clinical deployment: whether broad ApoB measurement identifies enough otherwise missed risk to justify routine use, and whether the resulting information leads to better decisions. Both papers accept the biological distinction between particle number and cholesterol content.

What ApoB testing can and cannot tell an individual patient

Someone with high triglycerides, type 2 diabetes, a history of heart attack or stroke, or unexpectedly low LDL-C during treatment may have a reason to discuss ApoB testing with a clinician. It is a complementary test, not a replacement for blood pressure assessment, smoking history, diabetes evaluation, family history or broader cardiovascular risk estimation.

ApoB is also distinct from lipoprotein(a), an inherited risk marker the 2026 guideline recommends measuring at least once in adulthood. An ApoB test does not identify how much of the particle burden comes specifically from lipoprotein(a).

Clinical treatment goals are risk-dependent. A laboratory value that is acceptable for one person may not be sufficient after a cardiovascular event. Decisions about starting or intensifying statins and other lipid-lowering treatments should follow a risk assessment rather than a single isolated biomarker. The finding that physical function can change years before some cardiovascular events, discussed in our cardiovascular aging report, also illustrates why no individual blood test captures every dimension of risk.

What the evidence cannot yet answer

The 2026 guideline reflects multiple lines of evidence, but the two September publications do not test whether a strategy of treating everyone to ApoB targets prevents more heart attacks or strokes than a strategy guided by accurate LDL-C and non-HDL-C measures. The NHANES analysis documents discordance; the viewpoint weighs clinical utility. Neither directly settles the outcome question.

Patients with metabolic disorders may benefit from a more complete picture of lipid risk, but whether an additional test changes treatment depends on existing risk factors, current therapy, assay availability and clinician judgment. The most defensible conclusion is not that LDL-C is obsolete or that everyone needs ApoB. It is that cholesterol mass and atherogenic particle number can differ, and sometimes that difference is clinically important.

References

  1. Blumenthal RS, et al. 2026 Guideline on the Management of Dyslipidemia. Circulation. 2026. DOI: 10.1161/CIR.0000000000001423.
  2. Cole J, Dufresne L, Toth PP, et al. Does the evidence support the ACC/AHA multisociety recommendation to measure apoB only after LDL-C and non-HDL-C are at target? Journal of Clinical Lipidology. 2026. DOI: 10.1016/j.jacl.2026.09.009.
  3. Razavi AC, Shapiro MD, Natarajan P, et al. Prioritizing Selective Use of Apolipoprotein-B Testing in the Era of Modern LDL-Cholesterol Calculation. JACC: Advances. 2026. DOI: 10.1016/j.jacadv.2026.103220.

Leave a Comment

Your email address will not be published. Required fields are marked *